Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plexin-A2 receptor (PLXNA2) is a single-pass transmembrane protein and a member of the plexin-A family, which acts as a co-receptor for specific semaphorins (notably SEMA3A, SEMA6A/B, and SEMA3C) and mediates axon repulsion and guidance during nervous system development[1][2][6]. By transducing semaphorin signals—often with neuropilin co-receptors—Plexin-A2 triggers cytoskeletal remodeling, directing neuron migration and networking. It plays critical roles in central nervous system development, cell migration, and, importantly, has been shown to promote cell proliferation and tumor growth (notably in glioblastoma)[3][7][8]. Mutations or abnormal expression of PLXNA2 are implicated in various neurological and developmental disorders, including intellectual disability, schizophrenia, and certain congenital anomalies[1][2]. High expression correlates with poor prognosis in some cancers, suggesting therapeutic relevance and potential as an anti-tumorigenic target[3].
Modulation of semaphorin interaction and downstream signaling; Regulation of cell proliferation pathways (e.g., via FARP2, FYN, AKT, and p38MAPK)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plexin-A2 receptor (PLXNA2).